BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

NCT01320280 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Stopped unexpectedly slow recruitment

Conditions

Refractory Cancer

Interventions

DRUG: BIBW 2992 (Afatinib)

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborators

[object Object]